780 related articles for article (PubMed ID: 26079639)
1. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
[TBL] [Abstract][Full Text] [Related]
2. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.
Frymoyer A; Hersh AL; Benet LZ; Guglielmo BJ
Pediatr Infect Dis J; 2009 May; 28(5):398-402. PubMed ID: 19295465
[TBL] [Abstract][Full Text] [Related]
3. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.
Revilla N; Martín-Suárez A; Pérez MP; González FM; Fernández de Gatta Mdel M
Br J Clin Pharmacol; 2010 Aug; 70(2):201-12. PubMed ID: 20653673
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
Arun A; Swamy S; Jacob K; Sharma R; Kohlhoff SA; Hammerschlag MR
Minerva Pediatr; 2018 Jun; 70(3):207-211. PubMed ID: 28006894
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients.
Silva DC; Seixas GT; Araujo OR; Arduini RG; Carlesse FA; Petrilli AS
Braz J Infect Dis; 2012; 16(4):361-5. PubMed ID: 22846125
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics and Dosing Optimization of Vancomycin in Pediatric Liver Transplant Recipients.
Shoji K; Saito J; Nakagawa H; Funaki T; Fukuda A; Sakamoto S; Kasahara M; Momper JD; Capparelli EV; Miyairi I
Microbiol Spectr; 2021 Oct; 9(2):e0046021. PubMed ID: 34612690
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic analysis of vancomycin in pediatric continuous renal replacement therapy.
Moffett BS; Morris J; Munoz F; Arikan AA
Eur J Clin Pharmacol; 2019 Aug; 75(8):1089-1097. PubMed ID: 30937470
[TBL] [Abstract][Full Text] [Related]
8. Improved vancomycin dosing in children using area under the curve exposure.
Le J; Bradley JS; Murray W; Romanowski GL; Tran TT; Nguyen N; Cho S; Natale S; Bui I; Tran TM; Capparelli EV
Pediatr Infect Dis J; 2013 Apr; 32(4):e155-63. PubMed ID: 23340565
[TBL] [Abstract][Full Text] [Related]
9. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD
Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357
[TBL] [Abstract][Full Text] [Related]
10. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
Frymoyer A; Guglielmo BJ; Hersh AL
Pediatr Infect Dis J; 2013 Oct; 32(10):1077-9. PubMed ID: 23652479
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates.
Mulubwa M; Griesel HA; Mugabo P; Dippenaar R; van Wyk L
Drugs R D; 2020 Jun; 20(2):105-113. PubMed ID: 32266599
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
13. Correlation of a Vancomycin Pharmacokinetic Model and Trough Serum Concentrations in Pediatric Patients.
Ploessl C; White C; Manasco K
Pediatr Infect Dis J; 2015 Oct; 34(10):e244-7. PubMed ID: 26121203
[TBL] [Abstract][Full Text] [Related]
14. Initial dosage regimen of vancomycin for septic shock patients: a pharmacokinetic study and Monte Carlo simulation.
Katip Bpharm W; Jaruratanasirikul S; Pattharachayakul S; Wongpoowarak W; Jitsurong A
J Med Assoc Thai; 2014 Nov; 97(11):1209-19. PubMed ID: 25675687
[TBL] [Abstract][Full Text] [Related]
15. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
[TBL] [Abstract][Full Text] [Related]
17. Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?
Hale CM; Seabury RW; Steele JM; Darko W; Miller CD
J Pharm Pract; 2017 Jun; 30(3):329-335. PubMed ID: 27074786
[TBL] [Abstract][Full Text] [Related]
18. Optimization of Intermittent Vancomycin Dosage Regimens for Thai Critically Ill Population Infected by MRSA in the Era of the "MIC Creep" Phenomenon.
Setiawan E; Suwannoi L; Montakantikul P; Chindavijak B
Acta Med Indones; 2019 Jan; 51(1):10-18. PubMed ID: 31073101
[TBL] [Abstract][Full Text] [Related]
19. First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients.
Flannery AH; Delozier NL; Effoe SA; Wallace KL; Cook AM; Burgess DS
Pharmacotherapy; 2020 Dec; 40(12):1210-1218. PubMed ID: 33176005
[TBL] [Abstract][Full Text] [Related]
20. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
